Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCTERNAL THERAPEUTICS, INC.

(ONCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Oncternal Therapeutics, Inc. Presents Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting

11/15/2021 | 08:00am EST

Oncternal Therapeutics, Inc. announced updated interim clinical data from the Phase 2 expansion cohort of its ongoing Phase 1/2 clinical trial evaluating ONCT-216 (formerly TK216), an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins, in patients with relapsed or refractory Ewing sarcoma. The data update was delivered in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting. ONCT-216 remains generally well tolerated. As of the October 1, 2021 data cutoff date, the most common drug-related adverse events included myelosuppression, fatigue, alopecia, nausea, pyrexia, and decreased appetite. The myelosuppression was primarily neutropenia, which was transient and readily managed. No unexpected off-target toxicities have been observed.


© S&P Capital IQ 2021
All news about ONCTERNAL THERAPEUTICS, INC.
01/26ONCTERNAL THERAPEUTICS : R&D Day, January 25, 2022
PU
01/25ONCTERNAL THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
01/20Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies..
GL
01/20Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies..
GL
01/05AFTER HOURS WATCH LIST SCORECARD : Wejo, onct, swim
MT
01/05ONCTERNAL THERAPEUTICS : Corporate Presentation, January 2022
PU
01/04MT NEWSWIRES AFTER HOURS WATCH LIST : Wejo, onct, swim
MT
01/04Oncternal Therapeutics Finalizes Study Design for Late-Stage Mantle Cell Lymphoma Trial..
MT
01/04Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Stud..
AQ
01/04Oncternal Therapeutics, Inc. Announces Agreement with U.S. FDA on Phase 3 Registrationa..
CI
More news
Analyst Recommendations on ONCTERNAL THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 5,08 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 82,5 M 82,5 M -
Capi. / Sales 2021 16,2x
Capi. / Sales 2022 32,8x
Nbr of Employees 13
Free-Float 87,7%
Chart ONCTERNAL THERAPEUTICS, INC.
Duration : Period :
Oncternal Therapeutics, Inc. Technical Analysis Chart | ONCT | US68236P1075 | MarketScreener
Technical analysis trends ONCTERNAL THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,67 $
Average target price 15,50 $
Spread / Average Target 828%
Managers and Directors
James B. Breitmeyer President, Chief Executive Officer & Director
Richard Glenn Vincent Chief Financial Officer, Secretary & Treasurer
David F. Hale Director
Rajesh Krishnan Chief Technology Officer
Gunnar F. Kaufmann Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCTERNAL THERAPEUTICS, INC.-26.43%83
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892